Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
November 28, 2018
AAM
BCBS: It’s time to CREATE more choices & lower drug prices
Blog
October 31, 2018
AAM
Prescription Drug Safety: Education and Impact
Blog
October 31, 2018
AAM
Prescription for Hope: AAM Members and Direct Relief
Blog
October 29, 2018
AAM
Women in Health Policy Gather at AAM
Blog
October 10, 2018
AAM
Generic and Biosimilars Approvals Are Only Half the Story
Blog
October 9, 2018
AAM
Op-Ed: The New NAFTA Could Thwart President’s Promise to Lower Prescription Drug Costs
Blog
September 21, 2018
AAM
$13.4 Billion a Year! Brand “Shenanigans” Are Costing Patients More Than Ever
Blog
September 20, 2018
AAM
Generic Prescriptions Save Lives… and Money, Too
Blog
September 19, 2018
AAM
10 Takeaways from the Savings Report
Blog
September 14, 2018
AAM
Recap: Highlights From the First GRx+Biosims Conference
Blog
August 30, 2018
AAM
Why Seniors Are Paying More as Drug Prices Fall
Blog
August 30, 2018
AAM
Four Reasons Why – The Benefits of AAM Membership
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH